A detailed history of Ubs Asset Management Americas Inc transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 894,217 shares of NBIX stock, worth $110 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
894,217
Previous 912,064 1.96%
Holding current value
$110 Million
Previous $126 Million 18.01%
% of portfolio
0.03%
Previous 0.04%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$114.58 - $153.15 $2.04 Million - $2.73 Million
-17,847 Reduced 1.96%
894,217 $103 Million
Q2 2024

Aug 13, 2024

BUY
$130.86 - $143.19 $40.9 Million - $44.8 Million
312,640 Added 52.16%
912,064 $126 Million
Q1 2024

May 15, 2024

SELL
$130.4 - $143.74 $2.35 Million - $2.59 Million
-18,029 Reduced 2.92%
599,424 $82.7 Million
Q4 2023

Feb 14, 2024

BUY
$106.07 - $132.76 $2.99 Million - $3.74 Million
28,162 Added 4.78%
617,453 $81.4 Million
Q3 2023

Nov 13, 2023

BUY
$94.02 - $117.1 $1.92 Million - $2.39 Million
20,413 Added 3.59%
589,291 $66.3 Million
Q1 2023

May 15, 2023

BUY
$94.11 - $123.02 $2.47 Million - $3.23 Million
26,266 Added 4.84%
568,878 $57.6 Million
Q4 2022

Feb 14, 2023

BUY
$106.72 - $127.06 $3.05 Million - $3.63 Million
28,586 Added 5.56%
542,612 $64.8 Million
Q3 2022

Nov 14, 2022

BUY
$92.03 - $107.81 $1.45 Million - $1.7 Million
15,788 Added 3.17%
514,026 $54.6 Million
Q2 2022

Aug 12, 2022

SELL
$75.79 - $100.07 $1.31 Million - $1.73 Million
-17,330 Reduced 3.36%
498,238 $48.6 Million
Q1 2022

May 16, 2022

BUY
$72.45 - $94.81 $12 Million - $15.7 Million
165,198 Added 47.15%
515,568 $48.3 Million
Q4 2021

Feb 14, 2022

BUY
$79.65 - $106.22 $6.06 Million - $8.08 Million
76,040 Added 27.72%
350,370 $29.8 Million
Q3 2021

Nov 15, 2021

BUY
$86.18 - $99.03 $1.51 Million - $1.74 Million
17,566 Added 6.84%
274,330 $26.3 Million
Q2 2021

Aug 16, 2021

SELL
$89.43 - $102.27 $15.1 Million - $17.2 Million
-168,462 Reduced 39.62%
256,764 $25 Million
Q1 2021

May 14, 2021

SELL
$87.57 - $119.4 $21.5 Million - $29.3 Million
-245,739 Reduced 36.62%
425,226 $41.4 Million
Q4 2020

Mar 01, 2021

BUY
$86.91 - $108.33 $8.93 Million - $11.1 Million
102,801 Added 18.09%
670,965 $64.3 Million
Q3 2020

Nov 13, 2020

BUY
$96.16 - $135.15 $2.64 Million - $3.7 Million
27,403 Added 5.07%
568,164 $54.6 Million
Q2 2020

Aug 14, 2020

BUY
$85.09 - $130.36 $5.27 Million - $8.07 Million
61,881 Added 12.92%
540,761 $66 Million
Q1 2020

May 15, 2020

SELL
$75.11 - $113.76 $2.51 Million - $3.8 Million
-33,409 Reduced 6.52%
478,880 $41.4 Million
Q4 2019

Feb 14, 2020

BUY
$86.8 - $118.57 $9.01 Million - $12.3 Million
103,841 Added 25.42%
512,289 $55.1 Million
Q3 2019

Nov 14, 2019

SELL
$83.82 - $101.5 $2.59 Million - $3.14 Million
-30,902 Reduced 7.03%
408,448 $36.8 Million
Q2 2019

Aug 15, 2019

BUY
$72.24 - $91.27 $2.07 Million - $2.61 Million
28,628 Added 6.97%
439,350 $0
Q1 2019

May 14, 2019

BUY
$69.31 - $91.53 $2.1 Million - $2.78 Million
30,346 Added 7.98%
410,722 $0
Q4 2018

Feb 13, 2019

BUY
$68.32 - $124.36 $14.8 Million - $26.9 Million
216,131 Added 131.59%
380,376 $27.2 Million
Q3 2018

Nov 14, 2018

SELL
$98.88 - $125.85 $19.7 Million - $25 Million
-198,975 Reduced 54.78%
164,245 $0
Q2 2018

Aug 14, 2018

SELL
$75.3 - $105.99 $1.26 Million - $1.77 Million
-16,719 Reduced 4.4%
363,220 $0
Q1 2018

May 14, 2018

SELL
$75.88 - $92.43 $6.47 Million - $7.88 Million
-85,253 Reduced 18.33%
379,939 $0
Q4 2017

Feb 09, 2018

SELL
$58.53 - $77.59 $3.19 Million - $4.23 Million
-54,520 Reduced 10.49%
465,192 $0
Q3 2017

Nov 13, 2017

BUY
$47.97 - $61.28 $24.9 Million - $31.8 Million
519,712
519,712 $0

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $11.8B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Ubs Asset Management Americas Inc Portfolio

Follow Ubs Asset Management Americas Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.